TGI.

2024

1. Ben Khaled N, Möller M, Jochheim LS, Leyh C, Ehmer U, Böttcher K, Pinter M, Balcar L, Scheiner B, Weich A, Leicht HB, Zarka V, Ye L, Schneider J, Piseddu I, Öcal O, Rau M, Sinner F, Venerito M, Gairing SJ, Förster F, Mayerle J, De Toni EN, Geier A, An Reiter FP. Atezolizumab/bevacizumab or lenvatinib in hepatocellular carcinoma: Multi-center real world study with focus on bleeding and thromboembolic events. J Hep Reports, 2024.

2022

Wiedemann, GM. Localization Matters: Epigenetic Regulation of Natural Killer Cells in Different Tissue Microenvironments. Invited Review. Frontiers In Immunology, 2022.

Göbel S, Kortum F, Chavez KJ, Jordan I, Sandig V, Reichl U, Altomonte J, Genzel Y. Cell-line screening and process development for a fusogenic oncolytic virus in small-scale suspension cultures. Appl Microbiol Biotechnol., 2022.

2021

Deschler S, Kager J, Erber J, Fricke L, Koyumdzhieva P, Georgieva A, Lahmer T, Wiessner JR, Voit F, Schneider J, Horstmann J, Iakoubov R, Treiber M, Winter C, Ruland J, Busch DH, Knolle PA, Protzer U, Spinner CD, Schmid RM, Quante M and Böttcher K. Mucosal-associated invariant T (MAIT) cells are highly activated and functionally impaired in COVID-19 patients. Viruses, 2021. 

Böttcher K, Longato L, Marrone G, Mazza G, Ghemtio L, Hall A, Luong TV, Caruso S, Viollet B, Zucman-Rossi J, Pinzani M and Rombouts K. AICAR and Compound C negatively modulate HCC-induced primary human hepatic stellate cell activation in vitro. American Journal of Physiology Gastrointestinal and Liver Physiology, 2021.

Lau CM, Wiedemann GM, Sun JC. Epigenetic regulation of natural killer cell memory. Invited Review. Immunological Reviews, 2021.

Wiedemann GM, Schneider J, Verbeek M, Konukiewitz B, Spinner CD, Einwächter H, Schmid RM, Rothe K.  An Eschar-like souvenir from a journey to Colombia: Ecthyma gangrenosum as a differential diagnosis of tropical diseases in immunocompromised patients – a case report. BMC Infectious Diseases, 2021.

Wiedemann GM, Santosa E, Grassman S, Sheppard S, Le Luduec JB, AdamsNM, Dang C, Hsu KC, Sun JC, Lau CM. Deconvoluting global cytokine signaling networks in natural killer cells. Nature Immunology 2021.

Reale A, Calistri A, Altomonte J. Giving oncolytic viruses a free ride: Carrier cells for oncolytic virotherapy. Pharmaceutics, 2021.

Nettelbeck DM, Leber MF, Altomonte J, Angelova A, Beil J, Berchtold S, Delic M, et al. Virotherapy in Germany – Recent activities in virus engineering, preclinical development, and clinical studies. Viruses, 2021.

Krabbe T, Marek J, Groll T, Steiger K, Schmid RM, Krackhardt AM, Altomonte J. Adoptive T cell therapy is complemented by oncolytic virotherapy with fusogenic VSV-NDV in combination treatment of murine melanoma. Cancers, 2021.

2020

Huber W, Lorenz G, Heilmaier M, Böttcher K, Sahm P, Middelhoff M, Ritzer B, Schulz D, Bekka E, Hesse F, Poszler A, Geisler F, Spinner CD, Schmid RM and Lahmer T. Extracorporeal multiorgan support including CO2-removal with the ADVanced Organ Support (ADVOS) system for COVID-19: A case report. The International Journal of Artificial Organs, 2020. 

Wiedemann GM, Grassmann S, Lau CM, Rapp M, Villarino AV, Friedrich C, Gasteiger G, O’Shea JJ, Sun JC. Divergent Role for STAT5 in the Adaptive Responses of Natural Killer Cells. Cell Reports 2020.

Piseddu I, Röhrle N, Knott MML, Moder S, Eiber S, Schnell K, Vetter V, Meyer B, Layritz P, Kühnemuth B, Wiedemann GM, Gruen J, Perleberg C, Rapp M, Endres S, Anz D. Constitutive expression of CCL22 is mediated by T cell-derived GM-CSF. Journal of Immunology 2020. 

Wiedemann GM, Geary CD, Lau CM, Sun JC. Cutting Edge: STAT1-Mediated Epigenetic Control of Rsad2 Promotes Clonal Expansion of Antiviral NK Cells. Journal of Immunology, 2020. 

2019

Mazza G, Telese A, Al-Akkad W, Frenguelli L, Levi A, Maralli M, Longato L, Thanapirom K, Vilia MG, Lombardi B, Crowley C, Crawford M, Karsdal MA, Leeming DJ, Marrone G, Bottcher K, et al. Cirrhotic Human Liver Extracellular Matrix 3D Scaffolds Promote Smad-Dependent TGF-b1 Epithelial Mesenchymal Transition. Cells, 2019 

Wiedemann GM, Röhrle N, Makeschin MC, Fesseler J, Endres S, Mayr D, Anz D. Peritumoral CCL1 and CCL22 expressing cells in hepatocellular carcinomas shape the tumor immune infiltrate. Pathology, 2019. 

2018

Böttcher K, Rombouts K, Saffioti F, Roccarina D, Rosselli M, Hall A, Luong T, et al. MAIT cells are chronically activated in patients with autoimmune liver disease and promote pro-fibrogenic hepatic stellate cell activation. Hepatology, 2018

Alberts R, de Vries EMG, Goode EC, Jiang X, Sampaziotis F, Rombouts K, Böttcher K, et al. Genetic association analysis identifies variants associated with disease progression in primary sclerosing cholangitis. Gut, 2018

Marrone G, De Chiara F, Böttcher K, Levi A, Dhar D, Longato L, Mazza G, et al. The adenosine monophosphate-activated protein kinase-vacuolar adenosine triphosphatase-pH axis: A key regulator of the profibrogenic phenotype of human hepatic stellate cells. Hepatology, 2018

Kuehnemuth B, Piseddu I, Wiedemann GM, Lauseker M, Kuhn C, Hofmann S, Schmoeckel E, Endres S, Mayr D. Jeschke U, Anz D. CCL1 is a major regulatory T cell attracting factor in human breast cancer. BMC Cancer, 2018. 

Wiedemann GM, Aithal C, Kraechan A, Heise C, Cadilha BL, Zhang J, Duewell P, Ballotti R, Endres S, Bertolotto C, Kobold, S. Microphthalmia-associated transcription factor (MITF) regulates immune cell migration into melanoma. Translational Oncology, 2018.

Rapp M, Wiedemann GM, Sun J. Memory responses of innate lymphocytes and parallels with T cells. Review. Seminars in Immunopathology, 2018.

Melzer MK, Zeitlinger L, Mall S, Steiger K, Schmid RM, Ebert O, Krackhardt A, and Altomonte J.  Enhanced safety and efficacy of oncolytic VSV therapy by combination with T cell receptor transgenic T cells as carriers. Mol Ther Oncolytics, 2018. 

Abdullahi S, Jäkel M, Behrend SJ, Steiger K, Topping G, Krabbe T, Colombo A, Sandig V, Schiergens TS, Thasler WE, Werner J, Lichtenthaler SF, Schmid RM, Ebert O, and Altomonte J.  A novel chimeric oncolytic virus vector for improved safety and efficacy in hepatocellular carcinoma. J Virol, 2018. 

Krabbe T and Altomonte J.  Fusogenic viruses in oncolytic immunotherapy. Cancers, 2018. 

Altomonte J.  (2018) Liver cancer:  Sensitizing hepatocellular carcinoma to ocolytic virus therapy.  Nat Rev Gastroenterol Heptatol, 2018.

2017

Böttcher K, Pinzani M. Pathophysiology of liver fibrosis and the methodological barriers to the development of anti-fibrogenic agents. Advanced Drug Delivery Reviews, 2017

Singh HD, Otano I, Rombouts K, Singh KP, Peppa D, Gill US, Böttcher K, et al. TRAIL regulatory receptors constrain human hepatic stellate cell apoptosis. Scientific Reports, 2017

Melzer MK, Lopez-Martinez A, Altomonte J.  (2017)  Oncolytic vesicular stomatitis virus as a viro-immunotherapy:  defeating cancer with a “hammer” and “anvil”.  Biomedicines, 2017. 

2016

Wiedemann GM, Jacobi SJ, Chaloupka M, Krächan A, Hamm S, Strobl S, Baumgartner R, Rothenfusser S, Duewell P, Endres S, Kobold S. A novel TLR7 agonist reverses NK cell anergy and cures RMA-S lymphoma-bearing mice. Oncoimmunology, 2016. 

Wiedemann GM, Knott MML, Vetter V, Rapp M, Haubner S, Fesseler J, Layritz P, Thaler R, Kruger S, Ormanns S, Mayr D, Endres S, Anz D. Cancer cell-derived IL-1α induces CCL22 and the recruitment of regulatory T cells. Oncoimmunology, 2016.

Altomonte J, Muñoz-Alvarez K, Shinozaki K, Baumgartner C, Kaissis G, Braren R, and Ebert O. Transarterial administration of oncolytic viruses for locoregional therapy of orthotopic HCC in rats.  JoVE, 2016.

2015

Anz, D., Rapp M, Eiber S, Koelzer VH, Thaler R, Haubner S, Knott M, Nagel S,  Golic M, Wiedemann GM, Bauernfeind F, Wurzenberger C, Hornung V, Scholz C, Mayr D, Rothenfusser S, Endres S and Bourquin C. Suppression of intratumoral CCL22 by type I interferon inhibits migration of regulatory T cells and blocks cancer progression. Cancer Research 2015

Marozin S, Altomonte J, Muñoz-Álvarez KA, De Toni EN, Thasler WE, Schmid RM, Ebert O.  STAT3 inhibition reduces toxicity of oncolytic VSV and provides a potentially synergistic combination therapy for hepatocellular carcinoma. Cancer Gene Ther, 2015.

Almstätter I, Mykhaylyk O, Settles M, Altomonte J, Aichler M, Walch A, Rummeny EJ, Ebert O, Plank C, Braren R.  Characterization of magnetic viral complexes for targeted delivery in oncology.  Theranostics,  2015. 

Muñoz-Álvarez KA, Altomonte J, Laitinen I, Ziegler S, Steiger K, Esposito I, Schmid RM, Ebert O.  PET imgaging of oncolytic VSV expressing the mutant HSV-1 thymidine kinase transgene in a preclinical HCC rat model.  Mol Ther, 2015. 

2014

Schölzel K, Schildberg FA, Welz M, Börner C, Geiger S, Kurts C, Heikenwälder M, et al. Transfer of MHC-class-I molecules among liver sinusoidal cells facilitates hepatic immune surveillance. Journal of Hepatology, 2014

Kobold S, Wiedemann G, Rothenfußer S, Endres S. Modes of action of TLR7 agonists in cancer therapy. Review, Immunotherapy, 2014. 

Altomonte J and Ebert O.  Sorting out Pandora’s box: discerning the dynamic roles of liver microenvironment in oncolytic virus therapy for hepatocellular carcinoma. Frontiers in Immunol, 2014.